June 04, 2026
Investors seeking final approval of a $78 million securities fraud settlement with Catalent told a New Jersey federal court that the proposed deal and fee bid are free of objections, arguing the positive response further supports the court's approval of the settlement.
May 08, 2026
Catalent Inc. agreed on Thursday to pay $78 million to settle a securities class action from a group of investors who alleged the vaccine manufacturer engaged in accounting and channel stuffing schemes and cut corners on safety to pad its revenues.